BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH to Create a New Global Leader in Metabolomics and Early Disease Detection
Innsbruck, Austria – January 3rd, 2018 – BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, announced today the acquisition of Metanomics Health GmbH. Metanomics Health is a metabolomics biomarker development and healthcare services specialist based in Berlin, Germany. At the same time, the company is closing a significant financing round to support future growth. BASF Plant Science GmbH, the former owner of Metanomics Health GmbH, will keep a minority share of BIOCRATES Life Sciences AG. The complementary skills and technologies of the merged companies will enable BIOCRATES to serve the fast-growing metabolomics market as total solution provider, with a focus on healthcare and pharmaceutical applications. The joint company will now culminate years of metabolomics-based discovery in the development, approval and marketing of novel diagnostics, aiming to become the world leader in early disease detection.
“Together, BIOCRATES and Metanomics Health provide the broadest technology and metabolomics product portfolio in the industry. These will enable us to provide deep metabolic phenotyping through targeted metabolomics profiling services, customized assays, targeted screening kits, and comprehensive data interpretation. Moreover, the merger will enable us to develop kits for both Diagnostics and Companion Diagnostics”, said BIOCRATES’ CEO Dr. Wulf Fischer-Knuppertz. “We are looking forward to further developing and expanding our offerings in the life science market. The completed financing round along with the merger allows us to increase our growth through accelerated kit development and regional sales expansion.”
BIOCRATES is the only worldwide company to provide metabolomics kits, which are capable of multiplexing for up to 400 metabolites across multiple analyte classes in a single run. These kits have contributed to more than 800 scientific publications and are being used in more than 100 mass spectrometry laboratories throughout the world. Metanomics Health contributes a rich portfolio of novel metabolite-based cancer and cardiometabolic clinical biomarkers addressing high unmet medical needs as well as a strong technical foothold in broad profiling with global service customers.
Dr. Tim Bölke, Metanomics Health’s Managing Director, who will continue to lead operations in Berlin and join the management team of BIOCRATES as Chief Medical Officer commented: “Metabolomics has the potential to bring a new dimension to diagnosis and patient stratification in precision medicine as well as to improve the drug discovery and development process. We are looking forward to extending and broadening our services and offerings to improve prognosis and diagnosis in areas of high unmet medical need, ultimately leading to earlier and better treatments.”
BASF Plant Science GmbH, MIG Fonds and GA Asset Fund GmbH & Co. KG (GAF) participated in the financing round.
Metabolomics is the comprehensive analysis of endogenous and exogenous small molecules such as lipids or amino acids, called metabolites. During the last couple of years, fingerprints of metabolites emerged as an essential biomarker approach in pharmaceutical and academic research. They allow researchers to better understand how genetic predisposition, together with lifestyle and environmental factors, influence health and the response to therapies. Metabolomics is a powerful technology that is increasingly being adopted in life sciences research and believed to have the potential of considerably contributing to population health and precision medicine.
About Metanomics Health GmbH
Metanomics Health GmbH is a healthcare company based in Berlin, Germany, hosting a state-of-the-art metabolite profiling facility providing highly robust and reproducible analysis of metabolite pathways and their changes in response to disease, pharmaceutical intervention and nutrition. This includes state-of-the-art statistics, proprietary bioinformatics tools with biomedical expert interpretation of mechanisms of action, new drug targets and predictive drug safety. For more information, please visit our website.
About BIOCRATES Life Sciences AG
Founded in 2002, BIOCRATES Life Sciences AG is a global leader in targeted metabolomics and offers unique solutions for the quantitative and quality-controlled measurement of more than 400 endogenous metabolites in kit format, and more than 800 metabolites as in-house contractual service. BIOCRATES is an Austrian company with corporate headquarters in Innsbruck and a subsidiary in the US. Throughout its growth from an academic spin-off to a global leader in metabolomics, BIOCRATES has been funded by leading financial and strategic investors including MIG Fonds and Bionorica S.E. For more information, please visit us on www.biocrates.com or follow us on LinkedIn.
Read press release here